- AU$11.95m
- AU$2.93m
- AU$7.71m
Immuron surges on positive data for diarrhea drug candidate
Australia's Immuron soars on positive trial results for gastric drug
Brief: Immuron Ltd Says Positive Results Support Travelan Progress To Phase 3 Clinical Trials In US
Brief: Immuron Seeks Trading Halt Pending Announcement On Phase 2 Imm-124E Clinical Trial Top-Line Results
Brief: Immuron Achieves Record Travelan Sales
Brief: Immuron Says Travelan Sales Ytd Jan 2024 Of A$2.7 Mln
Australia's Immuron eyes best day in 3 months on HY total sales
Brief: Immuron Says Total Sales Of A$2.4 Million In H1, FY24
Brief: Immuron Clinical Trials Update
Brief: Immuron Announces First Patients Enrolled In Campylobacter Challenge Clinical Study
Brief: Immuron Commences Travelan Clinical Study Cohort 2
Brief: Immuron Ltd Quarter one Sales A$1.57 Million
Australia's Immuron gains on record quarterly diarrhoea drug sales
Brief: Immuron Posts Total Sales Of A$1.6 Million In Q1 FY24
Australia's Immuron jumps on record monthly sales of Travelan in August
Brief: Immuron Says Sales Of Travelan® In August 2023 A$1.18 M
Brief: Immuron Ltd Receives TGA GMP Clearance
Australia's Immuron gains on nod for dispatch of diarrhoea drug
Brief: Immuron Says FY23 Sales Increase 136% On Fy22 Sales